Akers Biosciences to Present at 'Pioneers 2016' Investor Conference
May 04 2016 - 2:00PM
Marketwired
Akers Biosciences to Present at 'Pioneers 2016' Investor
Conference
THOROFARE, NJ-(Marketwired - May 4, 2016) - Akers Biosciences,
Inc. (NASDAQ: AKER) (AIM: AKR), (the "Company"), a developer of
rapid health information technologies, is presenting at Joseph
Gunnar & Co., LLC's 'Pioneers 2016' conference in New York on
May 5, 2016.
Co-founder and Chief Scientific Director, Raymond F. Akers, Jr.
PhD, will give a presentation on the Company to institutional and
accredited investors.
About Akers Biosciences, Inc.
Akers Biosciences develops, manufactures, and supplies rapid
screening and testing products designed to deliver quicker and more
cost-effective healthcare information to healthcare providers and
consumers. The Company has advanced the science of diagnostics
while responding to major shifts in healthcare through the
development of several proprietary platform technologies. The
Company's state-of-the-art rapid diagnostic assays can be performed
virtually anywhere in minutes when time is of the essence. The
Company has aligned with major healthcare companies and high volume
medical product distributors to maximize product offerings, and to
be a major worldwide competitor in diagnostics.
Additional information on the Company and its products can be
found at www.akersbio.com. Follow us on Twitter @AkersBio.
Cautionary Statement Regarding Forward Looking Statements
Statements contained herein that are not based upon current or
historical fact are forward-looking in nature and constitute
forward-looking statements within the meaning of Section 27A of the
Securities Act of 1933 and Section 21E of the Securities Exchange
Act of 1934. Such forward-looking statements reflect the Company's
expectations about its future operating results, performance and
opportunities that involve substantial risks and uncertainties.
These statements include but are not limited to statements
regarding the intended terms of the offering, closing of the
offering and use of any proceeds from the offering. When used
herein, the words "anticipate," "believe," "estimate," "upcoming,"
"plan," "target", "intend" and "expect" and similar expressions, as
they relate to Akers Biosciences, Inc., its subsidiaries, or its
management, are intended to identify such forward-looking
statements. These forward-looking statements are based on
information currently available to the Company and are subject to a
number of risks, uncertainties, and other factors that could cause
the Company's actual results, performance, prospects, and
opportunities to differ materially from those expressed in, or
implied by, these forward-looking statements.
For more information: Akers Biosciences, Inc. Raymond F. Akers,
Jr. PhD Co-founder and Chief Scientific Director Tel. +1 856 848
8698 Taglich Brothers, Inc. (Investor Relations) Chris Schreiber
Tel. +1 917 445 6207 Email: cs@taglichbrothers.com Vigo
Communications (Public Relations) Ben Simons / Fiona Henson Tel.
+44 (0)20 7830 9700 Email: akers@vigocomms.com
Akers Biosciences (NASDAQ:AKER)
Historical Stock Chart
From Jun 2024 to Jul 2024
Akers Biosciences (NASDAQ:AKER)
Historical Stock Chart
From Jul 2023 to Jul 2024